文献速递临床试验与 GCP流行病学与生物统计

海洋ω-3脂肪酸与维生素D补充对新发房颤的影响:一项随机临床试验

Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该研究为2×2析因随机试验的辅助研究,纳入25 119名50岁以上无心血管病、癌症及房颤的成人,随机接受EPA-DHA(460 mg/d EPA+380 mg/d DHA)、维生素D3(2000 IU/d)或安慰剂,中位随访5.3年。结果新发房颤在EPA-DHA组与安慰剂组(HR 1.09;95%CI 0.96-1.24;P=.19)、维生素D3组与安慰剂组(HR 1.09;95%CI 0.96-1.25;P=.19)均无显著差异。结论不支持使用二者用于新发房颤的一级预防。

要点

  • EPA-DHA与安慰剂相比新发房颤风险无显著差异(HR 1.09;95%CI 0.96-1.24)。
  • 维生素D3与安慰剂相比新发房颤风险亦无显著差异(HR 1.09;95%CI 0.96-1.25)。
  • 两种干预之间无交互作用(P=.39),不支持用于房颤一级预防。

核心结论

  • 在50岁以上成人中,EPA-DHA或维生素D3与安慰剂相比,中位随访5.3年内新发房颤风险无显著差异。
  • 研究结果不支持使用EPA-DHA或维生素D3用于新发房颤的一级预防。

研究设计与样本

  • 研究为2×2析因随机临床试验的辅助研究,纳入25 119名50岁以上、无既往心血管病、癌症或房颤的成人。
  • 参与者于2011年11月至2014年3月通过邮件在美国全部50个州招募,随访至2017年12月31日。
  • 随机分组:EPA-DHA+维生素D3(分析n=6272)、EPA-DHA+安慰剂(n=6270)、维生素D3+安慰剂(n=6281)、双安慰剂(n=6296)。
  • 干预剂量:EPA-DHA为每日460 mg EPA+380 mg DHA;维生素D3为每日2000 IU。
  • 主要终点为经病历审核确认的新发房颤;中位治疗和随访5.3年。

主要发现

  • 25 119名随机参与者(平均年龄66.7岁;50.8%女性)中,24 127人(96.1%)完成试验。
  • 中位5.3年随访期间,主要终点新发房颤发生在900名参与者中(占研究人群3.6%)。
  • EPA-DHA组与安慰剂组新发房颤分别为469例(3.7%)与431例(3.4%),HR 1.09;95%CI 0.96-1.24;P=.19。
  • 维生素D3组与安慰剂组新发房颤分别为469例(3.7%)与431例(3.4%),HR 1.09;95%CI 0.96-1.25;P=.19。
  • 两种研究药物之间无交互作用证据(P=.39)。

临床怎么用

  • 对于50岁以上无心血管病、癌症及房颤的成人,不应以EPA-DHA或维生素D3补充作为新发房颤的一级预防措施。
  • 临床决策中补充ω-3脂肪酸或维生素D时,无需以降低房颤风险为主要预期获益。

局限性

  • 原文未报告本辅助研究特有的局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atrial fibrillation (AF) is the most common heart rhythm disturbance, continues to increase in incidence, and results in significant morbidity and mortality. The marine omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and vitamin D have been reported to have both benefits and risks with respect to incident AF, but large-scale, long-term randomized trial data are lacking. OBJECTIVE: To test the effects of long-term administration of marine omega-3 fatty acids and vitamin D on incident AF. DESIGN, SETTING, AND PARTICIPANTS: An ancillary study of a 2 × 2 factorial randomized clinical trial involving 25 119 women and men aged 50 years or older without prior cardiovascular disease, cancer, or AF. Participants were recruited directly by mail between November 2011 and March 2014 from all 50 US states and were followed up until December 31, 2017. INTERVENTIONS: Participants were randomized to receive EPA-DHA (460 mg/d of EPA and 380 mg/d of DHA) and vitamin D3 (2000 IU/d) (n = 6272 analyzed); EPA-DHA and placebo (n = 6270 analyzed); vitamin D3 and placebo (n = 6281 analyzed); or 2 placebos (n = 6296 analyzed). MAIN OUTCOMES AND MEASURES: The primary outcome was incident AF confirmed by medical record review. RESULTS: Among the 25 119 participants who were randomized and included in the analysis (mean age, 66.7 years; 50.8% women), 24 127 (96.1%) completed the trial. Over a median 5.3 years of treatment and follow-up, the primary end point of incident AF occurred in 900 participants (3.6% of study population). For the EPA-DHA vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.24; P = .19). For the vitamin D3 vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.25; P = .19). There was no evidence for interaction between the 2 study agents (P = .39). CONCLUSIONS AND RELEVANCE: Among adults aged 50 years or older, treatment with EPA-DHA or vitamin D3, compared with placebo, resulted in no significant difference in the risk of incident AF over a median follow-up of more than 5 years. The findings do not support the use of either agent for the primary prevention of incident AF. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02178410; NCT01169259.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Albert CM, Cook NR, Pester J, et al. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2021. PMID: 33724323. doi:10.1001/jama.2021.1489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。